JP2020526538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526538A5 JP2020526538A5 JP2020501137A JP2020501137A JP2020526538A5 JP 2020526538 A5 JP2020526538 A5 JP 2020526538A5 JP 2020501137 A JP2020501137 A JP 2020501137A JP 2020501137 A JP2020501137 A JP 2020501137A JP 2020526538 A5 JP2020526538 A5 JP 2020526538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- bedaquiline
- months
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims description 17
- 229960000508 bedaquiline Drugs 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000011859 microparticle Substances 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 239000003607 modifier Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 3
- 241000186362 Mycobacterium leprae Species 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000008365 aqueous carrier Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- -1 fatty acid ester Chemical class 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 238000012153 long-term therapy Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 206010065048 Latent tuberculosis Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000033353 latent tuberculosis infection Diseases 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 2
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 2
- 229960002599 rifapentine Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022108846A JP7441276B2 (ja) | 2017-07-14 | 2022-07-06 | 長時間作用型配合物 |
| JP2023216574A JP7620692B2 (ja) | 2017-07-14 | 2023-12-22 | 長時間作用型配合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17181354 | 2017-07-14 | ||
| EP17181354.6 | 2017-07-14 | ||
| EP18167463.1 | 2018-04-16 | ||
| EP18167463 | 2018-04-16 | ||
| PCT/EP2018/069066 WO2019012100A1 (en) | 2017-07-14 | 2018-07-13 | EXTENDED ACTION FORMULATIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108846A Division JP7441276B2 (ja) | 2017-07-14 | 2022-07-06 | 長時間作用型配合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526538A JP2020526538A (ja) | 2020-08-31 |
| JP2020526538A5 true JP2020526538A5 (enExample) | 2021-08-19 |
| JP7102500B2 JP7102500B2 (ja) | 2022-07-19 |
Family
ID=62874924
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501137A Active JP7102500B2 (ja) | 2017-07-14 | 2018-07-13 | 長時間作用型配合物 |
| JP2022108846A Active JP7441276B2 (ja) | 2017-07-14 | 2022-07-06 | 長時間作用型配合物 |
| JP2023216574A Active JP7620692B2 (ja) | 2017-07-14 | 2023-12-22 | 長時間作用型配合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108846A Active JP7441276B2 (ja) | 2017-07-14 | 2022-07-06 | 長時間作用型配合物 |
| JP2023216574A Active JP7620692B2 (ja) | 2017-07-14 | 2023-12-22 | 長時間作用型配合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11141384B2 (enExample) |
| EP (3) | EP3651736B1 (enExample) |
| JP (3) | JP7102500B2 (enExample) |
| KR (2) | KR102679979B1 (enExample) |
| CN (2) | CN110869004B (enExample) |
| AU (1) | AU2018298855B2 (enExample) |
| BR (1) | BR112020000687A2 (enExample) |
| CA (1) | CA3069069A1 (enExample) |
| CO (1) | CO2020000328A2 (enExample) |
| CY (1) | CY1124782T1 (enExample) |
| DK (2) | DK3651736T3 (enExample) |
| ES (2) | ES2891976T3 (enExample) |
| FI (1) | FI3943070T3 (enExample) |
| HR (2) | HRP20240058T1 (enExample) |
| HU (2) | HUE064651T2 (enExample) |
| JO (1) | JOP20200004B1 (enExample) |
| LT (2) | LT3651736T (enExample) |
| MD (1) | MD3651736T2 (enExample) |
| MX (1) | MX393782B (enExample) |
| PE (1) | PE20200336A1 (enExample) |
| PH (1) | PH12020500076A1 (enExample) |
| PL (2) | PL3651736T3 (enExample) |
| RS (2) | RS65207B1 (enExample) |
| SA (1) | SA520410975B1 (enExample) |
| SI (2) | SI3943070T1 (enExample) |
| SM (2) | SMT202400033T1 (enExample) |
| UA (1) | UA126403C2 (enExample) |
| WO (1) | WO2019012100A1 (enExample) |
| ZA (1) | ZA202000215B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| JP7654544B2 (ja) * | 2018-12-13 | 2025-04-01 | マンカインド コーポレイション | ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法 |
| CA3182854A1 (en) * | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
| US20240277614A1 (en) * | 2020-07-09 | 2024-08-22 | Janssen Pharmaceutica Nv | Long-acting formulations |
| MX2023000439A (es) | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
| KR20230107275A (ko) * | 2020-11-12 | 2023-07-14 | 얀센 파마슈티카 엔.브이. | 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| WO2024068699A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US6495534B2 (en) | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| PT1888604E (pt) | 2005-05-25 | 2012-05-28 | Janssen Pharmaceutica Nv | Processo para preparar (alfa s, beta r)-6-bromo-alfa-[2- (dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil- 3-quinolinoetanol |
| HUE068406T2 (hu) | 2006-06-23 | 2024-12-28 | Janssen Sciences Ireland Unlimited Co | A TMC278 vizes szuszpenziója |
| UA97813C2 (uk) | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| US9421194B2 (en) | 2010-04-05 | 2016-08-23 | Rutgers, The State University Of New Jersey | Lung targeting dual drug delivery system |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| CA2832410C (en) | 2011-04-15 | 2019-07-23 | Janssen Pharmaceutica Nv | Freeze dried drug nanosuspensions |
| EP3177366A4 (en) | 2014-08-08 | 2018-04-04 | Pharmacyclics LLC | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| FI3250182T3 (fi) | 2015-01-27 | 2023-06-28 | Janssen Pharmaceutica Nv | Dispergoituvia koostumuksia |
| US10653679B2 (en) * | 2015-05-04 | 2020-05-19 | Board Of Trustees Of Michigan State University | Compositions and methods for inhibiting bacterial growth |
| HK1254620A1 (zh) | 2015-10-14 | 2019-07-26 | 结核病药物开发全球联盟公司 | 联合抗菌组合物以及短疗程抗菌方案 |
| RU2018111482A (ru) * | 2015-10-20 | 2019-11-21 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Кристаллические формы бедаквилин фумарата и способы их получения |
| WO2018226512A1 (en) | 2017-06-06 | 2018-12-13 | Merck Sharp & Dohme Corp. | Long-action implant for treatment of infectious diseases |
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| MX2023000439A (es) | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
| US20240277614A1 (en) | 2020-07-09 | 2024-08-22 | Janssen Pharmaceutica Nv | Long-acting formulations |
| CA3182854A1 (en) | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
-
2018
- 2018-07-13 SI SI201930692T patent/SI3943070T1/sl unknown
- 2018-07-13 PE PE2020000033A patent/PE20200336A1/es unknown
- 2018-07-13 HR HRP20240058TT patent/HRP20240058T1/hr unknown
- 2018-07-13 FI FIEP21178526.6T patent/FI3943070T3/fi active
- 2018-07-13 DK DK18739856.5T patent/DK3651736T3/da active
- 2018-07-13 SM SM20240033T patent/SMT202400033T1/it unknown
- 2018-07-13 UA UAA202000901A patent/UA126403C2/uk unknown
- 2018-07-13 HU HUE21178526A patent/HUE064651T2/hu unknown
- 2018-07-13 HR HRP20211450TT patent/HRP20211450T1/hr unknown
- 2018-07-13 DK DK21178526.6T patent/DK3943070T3/da active
- 2018-07-13 JO JOP/2020/0004A patent/JOP20200004B1/ar active
- 2018-07-13 BR BR112020000687-4A patent/BR112020000687A2/pt unknown
- 2018-07-13 US US16/630,676 patent/US11141384B2/en active Active
- 2018-07-13 MD MDE20200530T patent/MD3651736T2/ro unknown
- 2018-07-13 EP EP18739856.5A patent/EP3651736B1/en active Active
- 2018-07-13 PL PL18739856T patent/PL3651736T3/pl unknown
- 2018-07-13 MX MX2020000461A patent/MX393782B/es unknown
- 2018-07-13 EP EP21178526.6A patent/EP3943070B1/en active Active
- 2018-07-13 AU AU2018298855A patent/AU2018298855B2/en active Active
- 2018-07-13 RS RS20240102A patent/RS65207B1/sr unknown
- 2018-07-13 EP EP23206129.1A patent/EP4356968A3/en active Pending
- 2018-07-13 HU HUE18739856A patent/HUE055762T2/hu unknown
- 2018-07-13 RS RS20211178A patent/RS62362B1/sr unknown
- 2018-07-13 LT LTEPPCT/EP2018/069066T patent/LT3651736T/lt unknown
- 2018-07-13 PL PL21178526.6T patent/PL3943070T3/pl unknown
- 2018-07-13 ES ES18739856T patent/ES2891976T3/es active Active
- 2018-07-13 CA CA3069069A patent/CA3069069A1/en active Pending
- 2018-07-13 KR KR1020207003364A patent/KR102679979B1/ko active Active
- 2018-07-13 CN CN201880046696.8A patent/CN110869004B/zh active Active
- 2018-07-13 LT LTEP21178526.6T patent/LT3943070T/lt unknown
- 2018-07-13 SM SM20210557T patent/SMT202100557T1/it unknown
- 2018-07-13 ES ES21178526T patent/ES2970801T3/es active Active
- 2018-07-13 JP JP2020501137A patent/JP7102500B2/ja active Active
- 2018-07-13 KR KR1020247021329A patent/KR20240108542A/ko active Pending
- 2018-07-13 WO PCT/EP2018/069066 patent/WO2019012100A1/en not_active Ceased
- 2018-07-13 CN CN202210671005.1A patent/CN115252548A/zh active Pending
- 2018-07-13 SI SI201830409T patent/SI3651736T1/sl unknown
-
2020
- 2020-01-06 SA SA520410975A patent/SA520410975B1/ar unknown
- 2020-01-09 PH PH12020500076A patent/PH12020500076A1/en unknown
- 2020-01-13 ZA ZA2020/00215A patent/ZA202000215B/en unknown
- 2020-01-14 CO CONC2020/0000328A patent/CO2020000328A2/es unknown
-
2021
- 2021-09-08 US US17/469,021 patent/US12171887B2/en active Active
- 2021-09-23 CY CY20211100837T patent/CY1124782T1/el unknown
-
2022
- 2022-07-06 JP JP2022108846A patent/JP7441276B2/ja active Active
-
2023
- 2023-12-22 JP JP2023216574A patent/JP7620692B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526538A5 (enExample) | ||
| JP7441276B2 (ja) | 長時間作用型配合物 | |
| JP2013525431A5 (enExample) | ||
| EP2618815B1 (en) | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same | |
| WO2010015665A3 (en) | Parenteral composition comprising microspheres with a diameter between 10 and 20 microns | |
| JP2017523142A5 (enExample) | ||
| WO2012011192A1 (ja) | タクロリムスを含有する水中油型クリーム状組成物 | |
| JP2006524659A (ja) | ケラチノサイトの過剰増殖、特に、アトピー性皮膚炎および乾癬を特徴とする疾患を治療するためのリルゾールの使用 | |
| JP2016164204A (ja) | アリピプラゾール組成物 | |
| JP2011510001A (ja) | イミキモド製剤 | |
| US20170056345A1 (en) | Booster drug therapy for mycobacterium infections | |
| IL269296B2 (en) | A pharmaceutical preparation that includes high amounts of medium chain triglycerides and a related method | |
| AU2015323321A1 (en) | Long acting pharmaceutical compositions | |
| JP2016188187A (ja) | 外用医薬組成物 | |
| Young et al. | Inhaled pyrazinoic acid esters for the treatment of tuberculosis | |
| JP2016514706A5 (enExample) | ||
| JP2948111B2 (ja) | 経口投与用油性組成物 | |
| Mohan et al. | Newer anti-TB drugs and drug delivery systems | |
| JP5653401B2 (ja) | 乳化剤形の粉体含有皮膚外用剤の製造方法 | |
| JP7446711B2 (ja) | 皮膚外用組成物 | |
| JP2007063136A (ja) | 尿素配合外用製剤 | |
| CN114929335A (zh) | RORγt抑制剂及其局部用途 | |
| JP5063072B2 (ja) | 皮膚外用組成物 | |
| JP6704058B2 (ja) | プロテアーゼ阻害剤の長時間作用性医薬組成物 | |
| JP2019517490A (ja) | がん療法のためのメトロノミック経口ゲムシタビン |